In a recent study from an Italian NSCLC cohort involving both common and uncommon sensitizing EGFR mutations, a significant PFS benefit and a trend of improved OS toward bevacizumab plus erlotinib compared to erlotinib monotherapy groups were also noted [27]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.